Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
12,584,892
-
Total 13F shares
-
278,531
-
Share change
-
+28,531
-
Total reported value
-
$490,216
-
Price per share
-
$1.76
-
Number of holders
-
6
-
Value change
-
+$50,216
-
Number of buys
-
5
Institutional Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q2 2025
As of 30 Jun 2025,
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
278,531 shares.
The largest 6 holders included
Yorkville Advisors Global, LP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, Tower Research Capital LLC (TRC), BANK OF AMERICA CORP /DE/, and JPMORGAN CHASE & CO.
This page lists
6
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.